Answers are grounded in this paper and cite their sources.
A specially designed scintillation probe has been assembled and applied in a promising diagnostic study of malignant melanoma in the human eye. When used in conjunction with a new radiopharmaceutical agent recently developed at The University of Michigan, 125I labeled chloroquine analog, the probe permits simple and nonsurgical gamma ray counting as a substitute for more elaborate techniques required in 32p beta scanning for the same prupose. Preferential uptake of the agent in ocular melanomas has been previously reported using a modified 5-inch NaI (Tl) crystal scanner as the detector. We have realized a substantial improvement in both sensitivity and reproducibility by substituting a hand-held probe placed in contact with the patient's closed eyelid. The counting rate over each eye is followed for a period ranging from 3 to 21 days after dosage. A melanoma in one eye gives rise to an enhanced rate over that eye. Data are presented on a total of 12 patients, including two with confirmed ocular melanomas. In both of these cases, the involved eye consistently shows a significantly greater activity than the opposite eye. In the remaining cases considered "negative", measured eye-to-eye asymmtries are much lower, and a measure of the variance associated with these cases is presented.
No takes yet. Share an insight, caveat, or question.
Knoll et al. (1972) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: